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The responsiveness of the Action Research Arm (ARA) test
and the upper extremity motor section of the Fugl-Meyer
Assessment (FMA) scale were compared in a cohort of 22
chronic stroke patients undergoing intensive forced use
treatment aimed at improvement of upper extremity func-
tion. The cohort consisted of 13 men and 9 women, median
age 58.5 years, median time since stroke 3.6 years. Respon-
siveness was de ned as the sensitivity of an instrument to
real change. Two baseline measurements were performed
with a 2-week interval before the intervention, and a follow-
up measurement after 2 weeks of intensive forced use
treatment. The limits of agreement, according to the
Bland–Altman method, were computed as a measure of the
test-retest reliability. Two different measures of responsive-
ness were compared: (i) the number of patients who
improved more than the upper limit of agreement during
the intervention; (ii) the responsiveness ratio. The limits of
agreement, designating the interval comprising 95% of the
differences between two measurements in a stable indivi-
dual, were ¡5.7 to 6.2 and ¡5.0 to 6.6 for the ARA test and
the FMA scale, respectively. The possible sum scores range
from 0 to 57 (ARA) and from 0 to 66 (FMA). The number of
patients who improved more than the upper limit were 12
(54.5%) and 2 (9.1%); and the responsiveness ratios were
2.03 and 0.41 for the ARA test and the FMA scale,
respectively. These results strongly suggest that the ARA
test is more responsive to improvement in upper extremity
function than the FMA scale in chronic stroke patients
undergoing forced use treatment.
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INTRODUCTION
Rehabilitation of arm function after a stroke is an important
research topic. An increasing number of patients survive the
acute phase (1). In the Copenhagen Stroke Study, a population-
based study involving 88% of all stroke patients in a well-
de ned geographical area, it was found that 21% of the
surviving patients had not attained full upper extremity function
(de ned as independence while using both arms) (2), and 36%
had not attained independent walking function after compre-
hensive rehabilitation (3). The affected arm remained useless in
56% of the surviving patients in the sub-group with severe initial
upper extremity paresis (4). The function of the upper extremity
differs from the lower extremity with respect to the possibility of
compensation. Impaired upper extremity function can be
alleviated to some extent by compensation with the contralateral
upper extremity (4), even though this “unaffected” arm may not
function as well as the arm of a healthy subject (5).
One of the problems encountered in clinical trials to evaluate
the effect of rehabilitative interventions for the hemiparetic
upper extremity is the choice of valid, reliable and responsive
outcome measures. Outcome measures that focus on indepen-
dence in activities of daily living (ADL) are not speci c for the
motor function of the affected arm, because, at least theoreti-
cally, complete independence can also be achieved using only
one arm (2). Therefore, instruments focussing on independence
lack responsiveness to change in the function of the affected arm
itself. The responsiveness of a measurement instrument is its
sensitivity to true, clinically meaningful change (6–8). Different
criteria have been used as indicators of clinically meaningful
change, such as the change after an intervention of known
ef cacy (6) or the change in patients receiving the most effective
therapy in a randomized clinical trial (8).
The Action Research Arm (ARA) test (9) and the upper
extremity motor section of the Fugl-Meyer Assessment (FMA)
scale (10) have frequently been used in clinical trials to measure
improvement in the motor function of the affected arm itself (see
for instance references 11–14). The ARA test and the upper
extremity motor section of the FMA scale have been found to be
equally responsive in the  rst 8 weeks post-stroke, when most of
the recovery in arm function takes place (15). In a chronic
population the changes in arm function as a result of treatment
are expected to be much less impressive than in the  rst weeks
after a stroke (2). The purpose of this study is to compare the
responsiveness of the ARA test and the FMA scale in a chronic
stroke population receiving intensive forced use treatment,
which is aimed at improving dexterity and functional recovery
of the hemiparetic arm (14).
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METHODS
Patients and measurements
In a randomized clinical trial on the effectiveness of intensive forced use
therapy to improve the arm function in chronic stroke patients, the ARA
test and the FMA scale were used as outcome measures (14). Patients
were included if they met the following criteria: (i) a history of a single
stroke, at least 1 year previously, resulting in a hemiparesis on the
dominant side; (ii) a minimum of 20° of active extension in the wrist and
10° of  nger extension; (iii) ARA test score at intake below 51
(maximum score: 57); (iv) age 18–80 years; (v) able to walk indoors
without a stick, indicating no major balance problems; (vi) no severe
aphasia [score above P50 on the SAN (Stichting Afasie Nederland) test
(16)]; (vii) no severe cognitive impairments (Mini Mental State
Examination score of 22 or higher) (17). Sensory disorders were rated
on a dichotomous scale. Any sensory deviations reported by the patient
during the interview, or in a test involving alternating and simultaneous
touching of both hands (with eyes closed), were rated as positive.
Hemineglect was operationalized as a difference of at least two letters
between the unaffected and the affected side in the letter cancellation
test, or a signi cant (p< 0.05) deviation from the centre in a line
bisection test comprising of 10 lines of 10 cm, assessed by means of a
Wilcoxon signed rank sum test.
The protocol was approved by the University Hospital Medical Ethics
Committee, and all patients gave written informed consent. Two
baseline measurement s were performed with a 2-week interval before
the intervention commenced. A follow-up measurement took place
within 3 weeks after the start of the 2-week intervention period. The
experimental intervention, consisting of immobilization of the unaf-
fected arm by means of a splint and sling, combined with intensive
training of the affected arm for a period of 2 weeks, 5 days a week, 6
hours a day, was compared with an equally intensive reference
intervention of bimanual training (14).
A sub-sample of the patient population was included in the present
responsiveness study, based on the following additional criteria: (i) FMA
score at intake below 60 (maximum score: 66); (ii) allocated to the
experimental treatment; (iii) no missing values for any of the three
measurements; (iv) both baseline measurements performed by the same
rater. This sub-sample was compiled in such a way that improvement
was equally possible on the FMA (score <60; maximum: 66) and on the
ARA (score <51; maximum: 57), and the intervention currently
perceived to be most powerful was applied to these patients (18).
Measurement instruments
The FMA scale is a performance test, in which the patient is asked to
make movements that are considered to re ect the sequential stages of
hyperre exia,  exion and extension synergies, and the ability to perform
selective movements (10). The upper extremity motor function section
consists of 32 items which represent movement components , rated on a
three-point ordinal scale (0–2). The score of one item, re ex activity, is
doubled before calculating the sum score. The maximum sum score is
66, inferring optimal recovery. The FMA scale has been shown to be
valid (10) and reliable (19).
For the domain in which the function of one upper extremity in
purposeful activities is measured, Wade uses the term “focal disability”
(20). The ARA test is an example of a measurement instrument that
measures armfunction in this domain (9). It is aperformance test, inwhich
the ability to perform gross movements and the ability to grasp, move and
release objects differing in size, weight and shape, is tested. It consists of
19 items rated on a four-point ordinal scale (0–3). Summation of the 19
scores yields a sumscorewhich ranges from0 (noneof themovements can
be performed) to 57 (all movements are performed without dif culty).
The ARA test has been shown to be valid and reliable (9, 15, 21).
Responsiveness measures
Many different approaches have been described to quantify responsive-
ness (8). The responsiveness of an instrument cannot be evaluated
separately from its reliability (7). If an instrument shows a considerable
change in the mean score of patients after an intervention, this can only
be considered as an indication of the instrument’s responsiveness if it has
been shown to be reliable in a stable population (test-retest reproduci-
bility) (8). We used the following responsiveness measures shown
below.
Number of patients who improved more than the upper limit of
agreement during intensive therapy. The Bland–Altman method was  rst
used to evaluate the test-retest reproducibility (22). The limits of
agreement are de ned as the mean difference between the two measure-
ments per individual§ twice the standard deviation. The upper and lower
limits of agreement represent the “error thresholds” for improvement and
deterioration, respectively. Assuming a normal distribution of the
differences, just over 95% of the differences between the two measure-
ments per individual in a stable population will be between these limits
(22). The study population was considered to be stable between both
baseline measurements because the patients were all in the chronic phase
post-stroke (2). To compare the sensitivity to “real” (i.e. greater than the
“error threshold”) improvement for the ARA test and the FMA scale, the
numbers of patients who improved more than the upper limit of
agreement during the experimental intervention were compared.
The responsiveness ratio. According to Guyatt et al. (6) the
responsiveness ratio (RR) was computed as the ratio of the mean change
after the experimental intervention and the standard deviation of the
mean change during the baseline period.
RR ˆ mean improvement during intervention
standard deviation of mean difference baseline
A higher responsiveness ratio indicates greater responsiveness .
In both these approaches , undergoing the experimental intervention
was de ned as a criterion for improvement and the baseline period
represented stability.
RESULTS
The baseline characteristics of the 22 patients included in the
study are presented in Table I. The Bland–Altman scatter-plots
of the difference between baseline measurements against the
mean baseline score per individual are shown in Figs 1 and 2.
The mean difference and the limits of agreement, designating
the interval comprising 95% of the differences between two
measurements in a stable individual, are shown by the horizontal
lines. The means and standard deviations of the ARA and FMA
scores at the three subsequent measurement points and means
and standard deviations of the differences between these
measurements, as well as the limits of agreement and the
responsiveness ratios, are presented in Table II.
During the baseline period (14–20 days, median 15 days) the
mean change on either of the two instruments was small, 0.3 and
0.8 points for the ARA and the FMA, respectively, as is shown in
Figs. 1 and 2 and in Table II. The limits of agreement were ¡5.7
to 6.2 (Fig. 1) and ¡5.0 to 6.6 (Fig. 2) for the ARA test and the
Table I. Characteristics of the 22 chronic stroke patients included in
the present study
Median age (inter-quartil e range) 58.5 (53.2–63.2)
Median years since stroke
(inter-quartil e range) 3.6 (2.1–6.3)
Females (%) 9 (40.9)
Diagnosis of hemorrhage (%) 6 (27.3)
Left-sided hemiparesis (%) 4 (18.2)
Sensory disorders present (%) 12 (54.5)
Hemineglect present (%) 2 (9.1)
Median baseline* ARA score
(interquartile range) 38.0 (20.5–40.5)
Median baseline* FMA score
(interquartile range) 49.2 (41.5–54.9)
* Mean of baseline 1 and 2 per patient.
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FMA scale, respectively. This means that the difference between
two measurements has to be at least approximately 10% of the
total range of each scale (10.9% for the ARA, and 10.0% for the
FMA) to make measurement error unlikely, and to allow for the
conclusion that real change has occurred. The mean difference
after the intervention (20–27 days, median 21 days after the
second baseline measurement) was much larger for the ARA
(6.1 points) than for the FMA (1.2 points). The number of
patients who improved more than the upper limit of agreement
on the ARA test during the intervention period was 12 (54.5%),
compared to 2 (9.1%) on the FMA scale, indicating a
substantially larger responsiveness of the ARA test. This is
also re ected in the responsiveness ratios, 2.03 and 0.41 for the
ARA and the FMA, respectively.
DISCUSSION
Both methods applied in this study showed that the ARA test is
substantially more responsive to improvement in upper extremity
function than the FMA scale. This result is not in accordance
with the  ndings of De Weerdt & Harrison, who concluded that
the mean improvement on the ARA test and the FMA scale was
very similar, based on a scatter-plot of improvement on either
test between 2 and 8 weeks post-stroke in a cohort of 53 patients
(15). This difference in  ndings may be the result of the
difference in chronicity of the patients, or could be due to
methodological differences. It is conceivable that the improve-
ment during the  rst weeks to months of recovery takes place at a
level that differs from the domain in which the forced use
treatment has its effect. During the  rst weeks to months after a
stroke, the effect of rehabilitation combined with spontaneous
recovery results in improvement at both the impairment level and
at the disability level. De Weerdt & Harrison distinguished
“motor recovery”, represented by the subsequent stages of
movement in and out of synergy patterns, as measured by the
FMA scale, from “functional recovery”, which is more at the
disability level, as measured by the ARA test (15). There is no
simple relationship between improvement at the impairment and
disability levels (23). Therefore, and also because the forced use
treatment was speci cally aimed at the disability level, the
greater responsiveness of the ARA test found in the present study
is not surprising. The differences between these results and those
of De Weerdt & Harrison may also be due to a difference in the
initial arm function level of the included patients. Only one
patient in the present study population had a  rst baseline score
of less than 11 points on the ARA, and none of the patients scored
less than 11 points on the FMA, whereas more than half of the
patients in the De Weerdt & Harrison study scored less than 11
points on each test at the  rst measurement (15).
Although two different methods were used in this study to
assess responsiveness, the underlying assumption was the same:
the arm function of chronic stroke patients is stable between two
baseline measurements 2 weeks apart, and it improves during a
2-week intervention of intensive forced use therapy. Since an
established gold standard for improvement in arm function is
lacking, undergoing the intensive forced use treatment was used
as an external criterion for improvement. Although this
Table II. Means and standard deviations (SDs) of Action Research
Arm (ARA) and Fugl-Meyer Assessment (FMA) scores at three
subsequen t measurement points and of differences between these
measurements; limits of agreement and responsivenes s ratios
(n = 22)
ARA test FMA scale
Mean SD Mean SD
Baseline 1 30.9 11.9 48.0 8.2
Difference baseline 0.3 3.0 0.8 2.9
Baseline 2 31.2 10.8 48.8 8.1
Improvement 6.1 5.2 1.2 3.2
Follow-up 37.3 13.4 50.0 7.8
Limits of agreement1 ¡5.7 to 6.2 ¡5.0 to 6.6
Responsiveness ratio2 2.03 0.41
1 Mean difference baseline§2£ SD difference baseline.
2 Responsiveness ratio ˆ
mean improvement during intervention
standard deviation of mean difference baseline
:
Fig. 1. Scatter-plot of the difference between the two baseline
Action Research Arm (ARA) scores against the mean baseline
ARA score per individual . The horizontal lines show the mean of
the differences (middle) and the limits of agreement.
Fig. 2. Scatter-plot of the difference between the two baseline Fugl-
Meyer Assessment (FMA) scores against the mean baseline FMA
score per individual . The horizontal lines show the mean of the
differences (middle) and the limits of agreement.
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intervention has not yet been proven beyond doubt to be
effective (14), the  nding of a similar test-retest reproducibility
of ARA and FMA, as expressed in the limits of agreement,
supports the validity of the difference in responsiveness. In the
clinical trial (14), the experimental intervention of forced use
treatment was compared with a reference treatment of bimanual
training. The patients undergoing the reference treatment were
not included in this responsiveness study because bimanual
training in the chronic phase is not generally considered to be
effective. Alternatively, if the reference treatment could have
been considered to be merely placebo-treatment, the results in
the reference group could have been used to de ne stability.
However, taking the mean improvement (1.7 points on the ARA
test) during the reference intervention into account (14), the use
of the baseline period (with a mean improvement of 0.3 points
on the ARA test) to de ne stability was considered to be more
valid.
As stated earlier, responsiveness has to do with real, clinically
meaningful change. The de nition used to determine improve-
ment during the forced use treatment as clinically meaningful
remains arbitrary. Although attempts are made to assess the
minimal clinically important difference (MCID) empirically,
this is dif cult and, typically, very subjective (24). The limits of
agreement designate the smallest signal that can be detected
surmounting the test-retest “noise”. As such, these values are
merely statistical and bear no relationship to the MCID.
However, if the limits of agreement were found to encompass
the MCID, detection of a difference equal to the MCIDwould be
impossible. This would imply inability of the instrument to
detect changes that are considered to be clinically relevant (24).
At the start of the clinical trial (14), the MCID was arbitrarily set
at 10% of the total range of the scale, based on clinical
experience and estimates reported for similar outcome measures
in different domains (25). The resulting MCIDs of 5.7 and 6.6
points for the ARA test and the FMA scale, respectively, are
very similar to the limits of agreement found in this study.
It is therefore concluded that the ARA test and the upper
extremity motor section of the FMA scale are both reliable
enough to detect clinically relevant changes, but the ARA test is
substantially more responsive to improvement in upper ex-
tremity function in chronic stroke patients. Therefore, the ARA
test is recommended to evaluate changes in arm motor function
in chronic stroke patients.
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